Clinical characteristics and outcome of Covid-19 illness and predictors of in-hospital mortality in Saudi Arabia.

AUC Case fatality Comorbidities Disease severity Hospitalization ICU-admission Key parameters Laboratory findings Risk factors SARS-CoV-2

Journal

BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551

Informations de publication

Date de publication:
17 Dec 2022
Historique:
received: 20 03 2022
accepted: 13 12 2022
entrez: 16 12 2022
pubmed: 17 12 2022
medline: 21 12 2022
Statut: epublish

Résumé

Patients' race and ethnicity may play a role in mortality from Covid-19. Studies in China, the US, and Europe have been conducted on the predictors of Covid-19 mortality, yet in the EMR countries, such studies are scarce. Therefore, we aimed to describe the hospitalization rate, ICU-admission, and in-hospital mortality of Covid-19 and predictors of in-hospital mortality in Saudi Arabia. E-medical records were examined for all Covid-19 patients diagnosed in five tertiary hospitals affiliated with the Saudi-National Guard-Health Affairs during March 21, 2020, and September 12, 2021, based on a positive SARS-CoV-2 RT-PCR test, (n = 35,284). Data were collected on patients' characteristics, comorbidities, laboratory findings, hospitalization, ICU admission, and in-hospital and overall mortality. Logestic regressions were used to identify the independent predictors of in-hospital mortality. The best laboratory parameters cut-off values to predict in-hospital mortality were identified using the area under the receiver operating characteristic curve (AUC). Significance was considered at p < 0.05. Of all 35,284 Covid-19 patients, 81.8% were adults and 21.7% were hospitalized. Compared to non-hospitalized patients, hospitalized patients were more of female gender (52.1% versus 47.3%, p < 0.001) and had higher mean age (p < 0.001), higher mean BMI (p < 0.001), and higher rates of: diabetes (p < 0.001), hypertension (p < 0.001), ischemic heart disease (p < 0.001), cancer (p < 0.001), COPD (p < 0.001) and asthma (p = 0.011). The study showed 3.1% overall case-fatality, 20.3% ICU admission rate, and 9.7% in-hospital mortality. Predictors of in-hospital mortality among adult patients were; patients' age ≥ 70 years (OR = 6.93, 95% CI 1.94-24.79), ischemic heart disease (OR = 1.80, 95% CI 1.05-3.09), ICU admission (OR = 24.38, 95% CI 15.64-38.01), abnormal C-reactive protein "CRP" (OR = 1.85, 95% CI 1.08-3.16), abnormal D-dimer (OR = 1.96, 95% CI 1.15-3.36), lymphopenia (OR = 2.76, 95% CI 2.03-3.3.76), high neutrophil count (OR = 2.10, 95% CI 1.54-2.87), and abnormal procalcitonin (OR = 3.33, 95% CI 1.88-5.90). The best laboratory parameters cut-off values to predict in-hospital mortality were CRP > 72.25 mg/L (AUC = 0.64), D-dimer > 1125 µg/L (AUC = 0.75), neutrophils count > 5,745 × 10^9/L (AUC = 0.70), lymphocytic count < 1.10 × 10^9/L (AUC = 0.72), and procalcitonin > 0.18 ng/mL (AUC = 0.76). Rates of hospitalization, ICU-admission, in-hospital mortality and overall case fatality were nearly comparable to the rates in western countries. Early interventions are necessary for high-risk Covid-19 patients, especially elderly patients and those with cardiac diseases.

Sections du résumé

BACKGROUND BACKGROUND
Patients' race and ethnicity may play a role in mortality from Covid-19. Studies in China, the US, and Europe have been conducted on the predictors of Covid-19 mortality, yet in the EMR countries, such studies are scarce. Therefore, we aimed to describe the hospitalization rate, ICU-admission, and in-hospital mortality of Covid-19 and predictors of in-hospital mortality in Saudi Arabia.
METHODS METHODS
E-medical records were examined for all Covid-19 patients diagnosed in five tertiary hospitals affiliated with the Saudi-National Guard-Health Affairs during March 21, 2020, and September 12, 2021, based on a positive SARS-CoV-2 RT-PCR test, (n = 35,284). Data were collected on patients' characteristics, comorbidities, laboratory findings, hospitalization, ICU admission, and in-hospital and overall mortality. Logestic regressions were used to identify the independent predictors of in-hospital mortality. The best laboratory parameters cut-off values to predict in-hospital mortality were identified using the area under the receiver operating characteristic curve (AUC). Significance was considered at p < 0.05.
RESULTS RESULTS
Of all 35,284 Covid-19 patients, 81.8% were adults and 21.7% were hospitalized. Compared to non-hospitalized patients, hospitalized patients were more of female gender (52.1% versus 47.3%, p < 0.001) and had higher mean age (p < 0.001), higher mean BMI (p < 0.001), and higher rates of: diabetes (p < 0.001), hypertension (p < 0.001), ischemic heart disease (p < 0.001), cancer (p < 0.001), COPD (p < 0.001) and asthma (p = 0.011). The study showed 3.1% overall case-fatality, 20.3% ICU admission rate, and 9.7% in-hospital mortality. Predictors of in-hospital mortality among adult patients were; patients' age ≥ 70 years (OR = 6.93, 95% CI 1.94-24.79), ischemic heart disease (OR = 1.80, 95% CI 1.05-3.09), ICU admission (OR = 24.38, 95% CI 15.64-38.01), abnormal C-reactive protein "CRP" (OR = 1.85, 95% CI 1.08-3.16), abnormal D-dimer (OR = 1.96, 95% CI 1.15-3.36), lymphopenia (OR = 2.76, 95% CI 2.03-3.3.76), high neutrophil count (OR = 2.10, 95% CI 1.54-2.87), and abnormal procalcitonin (OR = 3.33, 95% CI 1.88-5.90). The best laboratory parameters cut-off values to predict in-hospital mortality were CRP > 72.25 mg/L (AUC = 0.64), D-dimer > 1125 µg/L (AUC = 0.75), neutrophils count > 5,745 × 10^9/L (AUC = 0.70), lymphocytic count < 1.10 × 10^9/L (AUC = 0.72), and procalcitonin > 0.18 ng/mL (AUC = 0.76).
CONCLUSIONS CONCLUSIONS
Rates of hospitalization, ICU-admission, in-hospital mortality and overall case fatality were nearly comparable to the rates in western countries. Early interventions are necessary for high-risk Covid-19 patients, especially elderly patients and those with cardiac diseases.

Identifiants

pubmed: 36526994
doi: 10.1186/s12879-022-07945-8
pii: 10.1186/s12879-022-07945-8
pmc: PMC9758036
doi:

Substances chimiques

Procalcitonin 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

950

Informations de copyright

© 2022. The Author(s).

Références

BMJ. 2003 Jun 21;326(7403):1358-62
pubmed: 12816821
Intensive Care Med. 2019 Jun;45(6):757-769
pubmed: 30888440
J Infect Public Health. 2022 Jan;15(1):13-20
pubmed: 34861603
Int J Surg. 2020 May;77:206-216
pubmed: 32289472
Lancet Digit Health. 2020 Oct;2(10):e516-e525
pubmed: 32984797
EBioMedicine. 2020 May;55:102763
pubmed: 32361250
Eur Respir J. 2020 May 7;55(5):
pubmed: 32269088
Diagnosis (Berl). 2020 May 26;7(2):91-96
pubmed: 32352401
J Med Virol. 2020 Jun;92(6):568-576
pubmed: 32134116
J Infect Dev Ctries. 2020 Feb 29;14(2):125-128
pubmed: 32146445
Am J Emerg Med. 2021 Jul;45:290-296
pubmed: 33041130
Biomark Med. 2020 Jul;14(10):827-837
pubmed: 32490680
Chin Med J (Engl). 2003 Jul;116(7):985-7
pubmed: 12890367
Pol Arch Intern Med. 2020 Apr 30;130(4):304-309
pubmed: 32231171
Saudi Med J. 2020 Nov;41(11):1217-1226
pubmed: 33130842
BMC Infect Dis. 2022 Mar 30;22(1):273
pubmed: 35351028
Nat Rev Endocrinol. 2020 Jul;16(7):341-342
pubmed: 32327737
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
BMC Infect Dis. 2020 Jun 23;20(1):445
pubmed: 32576139
J Infect. 2020 Aug;81(2):e59-e61
pubmed: 32353384
BMC Infect Dis. 2020 Sep 29;20(1):719
pubmed: 32993538
BMJ Glob Health. 2022 May;7(5):
pubmed: 35618305
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
Indian J Med Res. 2013 Nov;138(5):595-608
pubmed: 24434315
Arch Gerontol Geriatr. 2021 Jul-Aug;95:104383
pubmed: 33676091
BMJ Open. 2020 Sep 17;10(9):e038976
pubmed: 32948572
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Metabolism. 2020 Jul;108:154262
pubmed: 32422233
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Med Virol. 2020 Oct;92(10):1875-1883
pubmed: 32441789
J Infect. 2020 Apr;80(4):388-393
pubmed: 32112884
Saudi Med J. 2020 Sep;41(9):907-915
pubmed: 32893272
J Multidiscip Healthc. 2021 Apr 15;14:839-852
pubmed: 33883900
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
J Thromb Haemost. 2020 Jun;18(6):1324-1329
pubmed: 32306492
Chest. 2010 Sep;138(3):568-77
pubmed: 20435656
Open Forum Infect Dis. 2020 Apr 29;7(5):ofaa153
pubmed: 32455147
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
J Med Virol. 2020 Jul;92(7):791-796
pubmed: 32181911
Science. 2021 May 28;372(6545):
pubmed: 33906968
Lancet Infect Dis. 2020 Jun;20(6):669-677
pubmed: 32240634
J Med Virol. 2020 Nov;92(11):2409-2411
pubmed: 32516845
J Infect. 2020 Jun;80(6):656-665
pubmed: 32283155
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Am J Physiol Endocrinol Metab. 2020 May 1;318(5):E736-E741
pubmed: 32228322
J Clin Virol. 2020 Jun;127:104370
pubmed: 32344321
Eur J Clin Invest. 2020 Oct;50(10):e13362
pubmed: 32726868
N Engl J Med. 2020 Apr 30;382(18):1677-1679
pubmed: 32109012
Int J Gen Med. 2020 Nov 17;13:1157-1165
pubmed: 33244256
Saudi Pharm J. 2021 Jul;29(7):682-691
pubmed: 34400862
J Med Virol. 2020 Oct;92(10):1759-1760
pubmed: 32275075
Pharmacol Res. 2020 Aug;158:104931
pubmed: 32446978
J Epidemiol Glob Health. 2021 Mar;11(1):98-104
pubmed: 33095982
Intern Med J. 2020 Dec;50(12):1483-1491
pubmed: 33022124
J Infect Public Health. 2021 Aug;14(8):994-1000
pubmed: 34153731
JAMA Cardiol. 2020 Jul 1;5(7):802-810
pubmed: 32211816
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Obesity (Silver Spring). 2020 Jun;28(6):1005
pubmed: 32237206
Front Immunol. 2020 May 01;11:827
pubmed: 32425950
Ann Hematol. 2020 Jul;99(7):1421-1428
pubmed: 32495027
PLoS One. 2020 Nov 12;15(11):e0242127
pubmed: 33180830
Eur Respir J. 2020 May 14;55(5):
pubmed: 32217650
Clin Infect Dis. 2021 Dec 6;73(11):e4208-e4213
pubmed: 32173725
J Infect Public Health. 2021 Jun;14(6):717-723
pubmed: 34020211
BMC Infect Dis. 2022 Feb 8;22(1):136
pubmed: 35135491
J Infect Public Health. 2022 Jan;15(1):142-151
pubmed: 34764042
Aging Dis. 2019 Apr 1;10(2):367-382
pubmed: 31011483
BMC Med. 2014 Apr 10;12:61
pubmed: 24722122
Indian J Endocrinol Metab. 2012 Mar;16 Suppl 1:S27-36
pubmed: 22701840
JAMA. 2020 Jun 2;323(21):2195-2198
pubmed: 32329797
Health Sci Rep. 2022 May 05;5(3):e628
pubmed: 35539445
Ann Transl Med. 2021 Feb;9(3):201
pubmed: 33708828
Clin Chem Lab Med. 2020 Jun 25;58(7):1095-1099
pubmed: 32301746
J Leukoc Biol. 2017 Oct;102(4):977-988
pubmed: 28733462

Auteurs

Mostafa A Abolfotouh (MA)

King Abdullah International Medical Research Center, Mail Code 3533, Riyadh, Saudi Arabia. mabolfotouh@gmail.com.
King Saud Bin-Abdulaziz University for Health Sciences (KSAU-HS), Riyadh, Saudi Arabia. mabolfotouh@gmail.com.
King Abdulaziz Medical City, Ministry of National Guard-Health Affairs, POB 22490, Riyadh, 11426, Saudi Arabia. mabolfotouh@gmail.com.

Abrar Musattat (A)

King Abdullah International Medical Research Center, Mail Code 3533, Riyadh, Saudi Arabia.

Maha Alanazi (M)

King Abdullah International Medical Research Center, Mail Code 3533, Riyadh, Saudi Arabia.

Suliman Alghnam (S)

King Abdullah International Medical Research Center, Mail Code 3533, Riyadh, Saudi Arabia.
King Saud Bin-Abdulaziz University for Health Sciences (KSAU-HS), Riyadh, Saudi Arabia.

Mohammad Bosaeed (M)

King Abdullah International Medical Research Center, Mail Code 3533, Riyadh, Saudi Arabia.
King Saud Bin-Abdulaziz University for Health Sciences (KSAU-HS), Riyadh, Saudi Arabia.
King Abdulaziz Medical City, Ministry of National Guard-Health Affairs, POB 22490, Riyadh, 11426, Saudi Arabia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH